ClinicalTrials.gg
Drug

Abatacept clinical trials

Also written Orencia, Belatacept, Nulojix and BMS-188667.

studies test it
218
open now
28
in phase 3
51
first study started
1995

How each study uses Abatacept is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Abatacept studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
23 Dec 2005 · ORENCIA · BLA 125118 (FDA, Drugs@FDA)
European Union
21 May 2007 · Orencia · EMEA/H/C/000701 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Abatacept
128
CTLA4-Ig
6
Abatacept Injection
5
CTLA4Ig
3
Abatacept Prefilled Syringe
2

Brand

Orencia
101
Nulojix
30

Development codes

BMS-188667
29
BMS-224818
6
LEA29Y
2
ONO-4164
1
RG2077
1

Other names

Belatacept
47

Studies by the year they started

218 studies that test it; most in 2013 (23)

Studies that test Abatacept, by start year
YearStudies
19952
19971
20002
20012
20024
20033
20041
20056
20066
200714
200814
20093
20104
20119
20127
201323
201416
201512
20167
20174
20189
201912
202010
202113
202210
20237
20244
20256
20267

By phase

A phase 1/2 study counts in both.

Early Phase 1
7
Phase 1
43
Phase 2
97
Phase 3
51
Phase 4
36
No phase
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 68 · Other 150

Bristol-Myers Squibb (65) · National Institute of Allergy and Infectious Diseases (NIAID) (16) · Emory University (5) · NYU Langone Health (5) · University of California, Los Angeles (5) · Duke University (4) · Massachusetts General Hospital (4) · Columbia University (4)

Often tested with

Tested in the same studies.

Methotrexate (8) · Tocilizumab (8) · Adalimumab (7) · Certolizumab Pegol (6) · Sirolimus (6) · Etanercept (5) · Tofacitinib (5) · Infliximab (5)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 10, 2 in phase 3

Studies that test Abatacept, phase 3 first.

Studies

Open first, then newest update. How each study uses Abatacept is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 218

See all 218 studies that test Abatacept →

Given beside what is tested · 12 — Abatacept is usual care or a partner of the new treatment
As the comparator · 6 — what is tested is compared with Abatacept

Codes

What other systems call Abatacept · ClinicalTrials.gg INT006617

  • MeSH (NLM) D000069594AbataceptConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 7D0YB67S97ABATACEPTConfirmed FDA, NLM, Wikidata
  • RxNorm 614391Confirmed FDA, Wikidata
  • Wikidata Q2697833abataceptConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C28898AbataceptOne source FDA
  • DrugBank DB01281One source Wikidata

Also registered as belatacept (UNII E3B2GI648A · RxNorm 1112973).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.